Spyre Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Spyre Therapeutics, Inc. on March 18, 2024. The filing discloses the entry into a Material Definitive Agreement for a private placement of equity securities and related amendments to the company's charter documents.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of Series B Non-Voting Convertible Preferred Stock.
- Aggregate Purchase Price: Approximately $180.0 million.
- Shares Issued: 121,625 shares of Series B Preferred Stock.
- Price Per Share: $1,480.00.
- Conversion Ratio: Each Preferred Share converts into 40 shares of Common Stock.
- Pro Forma Capitalization: Following closing, the company expects 36,599,786 shares of Common Stock outstanding, rising to approximately 65.2 million shares on a fully converted basis (including Series A and Series B Preferred Stock and pre-funded warrants).
- Placement Agents: Jefferies LLC, Cowen and Company, LLC, Evercore Group L.L.C., Stifel, Nicolaus & Company, Incorporated, Guggenheim Securities, LLC, and LifeSci Capital LLC.
Material Changes and Agreements
The company entered into a Securities Purchase Agreement and a Registration Rights Agreement with institutional and accredited investors. The closing is expected on March 20, 2024. The company must file a registration statement for the resale of the underlying common stock within 30 days of closing or two business days after the effectiveness of its Form S-1, whichever is later, and use commercially reasonable efforts to have it declared effective within 90 days.
The company filed a Certificate of Amendment to increase the authorized shares of Series B Preferred Stock from 150,000 to 271,625. The Series B Preferred Stock is non-voting but carries protective provisions requiring holder approval for adverse changes to their rights. Dividends are payable on an as-if-converted basis.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, revenue projections, or management commentary on operational outlook. The primary risk disclosed relates to the requirement for stockholder approval of the conversion of Preferred Shares into Common Stock at the 2024 annual meeting. Additionally, conversion is subject to beneficial ownership limitations, where holders cannot convert if it would result in beneficial ownership exceeding a specified percentage (between 0% and 19.9%) of the total outstanding common stock.
Key Facts for Investor Verification
- Verify the closing date of the private placement (expected March 20, 2024) and the receipt of the $180.0 million proceeds.
- Confirm the outcome of the stockholder vote on the Conversion Proposal at the 2024 annual meeting.
- Monitor the filing and effectiveness of the registration statement for the resale of common stock issuable upon conversion.
- Review the final pro forma capitalization to understand the dilution impact on existing common shareholders.
- Check for any updates on the company's cash runway and operational milestones following the capital raise.